Stock News•1 months ago
Merck's Remigromig Meets Main Goal in Diabetic Macular Edema Study
Merck's remigromig met the primary goal in a diabetic macular edema study, showing non-inferiority to ranibizumab, with further safety analyses ongoing.
MarketLens
Is Regeneron's Eylea HD Enough to Fend Off Biosimilars and Rivals
6 months ago
SHARE THIS ON:
Exclusive Content for Pro Members
Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.
SHARE THIS ON:
Related Articles
Category
You may also like
Stock News•1 months ago
Regeneron Highlights EYLEA HD Momentum, Dupixent Growth and Pipeline Catalysts
Regeneron highlighted continued growth across key marketed products including EYLEA HD and Dupixent, plus a broad late-stage pipeline, during a discussion with Bernstein analyst Jeffrey Walch.
News•2 months ago
EyePoint After Lugano: Primary Endpoint Miss, Asymmetric Risk-Reward
EyePoint's wet-AMD drug LUGANO missed its primary endpoint, lowering estimated approval probability to 30% and raising regulatory risk. Strong durability results still support DURAVYU's commercial pot...
Breaking News
View All →Featured Articles
Top Headlines
Stock News•59 minutes ago
Jim Cramer sees major implications from SK Hynix's home-run quarter
Stock News•1 hour ago
Google parent Alphabet tumbles after profit disappoints, warns AI is battering its cash flow
Stock News•1 hour ago
Jim Cramer says these tech giants can weather market turbulence
Stock News•1 hour ago
Alphabet Inc. (GOOG) Misses Q3 Earnings and Revenue Estimates
Stock News•1 hour ago